Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PetMed Express, Inc. (PETS : NSDQ)
 
 • Company Description   
PetMed Express, Inc. and subsidiaries, d/b/a 1-800-PetMeds (the `Company`), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, and speed of delivery. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the `1-800-PetMeds` brand name, and `PetMeds` family of trademarks, increase traffic on its website at www.1800petmeds.com, acquire new customers, and maximize repeat purchases. The majority of the Company's sales are to residents in the United States. The Company's corporate headquarters and distribution facility are located in Delray Beach, Florida.

Number of Employees: 287

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.29 Daily Weekly Monthly
20 Day Moving Average: 133,388 shares
Shares Outstanding: 20.66 (millions)
Market Capitalization: $67.96 (millions)
Beta: 0.78
52 Week High: $6.85
52 Week Low: $2.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.92% -20.61%
12 Week 8.22% -7.56%
Year To Date -31.74% -36.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
420 SOUTH CONGRESS AVENUE
-
DELRAY BEACH,FL 33445
USA
ph: 561-526-4444
fax: 561-526-4445
investor@petmeds.com http://www.1800petmeds.com
 
 • General Corporate Information   
Officers
Sandra Y. Campos - Chief Executive Officer; President and Director
Leslie C.G. Campbell - Chair of the Board and Director
Christine Chambers - Chief Financial Officer and Treasurer
Gian M. Fulgoni - Director
Diana Garvis Purcel - Director

Peer Information
PetMed Express, Inc. (COOL.)
PetMed Express, Inc. (GFME)
PetMed Express, Inc. (GSVI)
PetMed Express, Inc. (GDENZ)
PetMed Express, Inc. (EMUS)
PetMed Express, Inc. (BFLY.)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: INTERNET COMMERCE
Sector: Retail/Wholesale
CUSIP: 716382106
SIC: 5912
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 20.66
Most Recent Split Date: (:1)
Beta: 0.78
Market Capitalization: $67.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.07 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 109.67
Trailing 12 Months: 329.00
PEG Ratio: -
Price Ratios
Price/Book: 0.71
Price/Cash Flow: 144.35
Price / Sales: 0.28
EPS Growth
vs. Year Ago Period: 70.00%
vs. Previous Quarter: -127.27%
Sales Growth
vs. Year Ago Period: -18.88%
vs. Previous Quarter: -11.06%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - 0.37
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - 0.23
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.43
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 1.18
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - 0.14
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - 0.14
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - 0.78
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 4.65
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 9.05
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©